Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527634 | 0.88 | AR (0.47) | ALDH1A1ARMAPTLMNAMEN1 | |
| SCHEMBL18527851 | 0.88 | AR (0.47) | ALDH1A1ARMAPTLMNAMEN1 | |
| SCHEMBL18540928 | 0.77 | HPGD (0.47) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL18540952 | 0.77 | HPGD (0.47) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL18540988 | 0.77 | AR (0.51) | AR | |
| SCHEMBL18540985 | 0.77 | AR (0.51) | AR | |
| SCHEMBL18540946 | 0.77 | HPGD (0.49) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL18540930 | 0.77 | HPGD (0.49) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL18541023 | 0.72 | SIRT6 (0.39) | ALDH1A1ARMAPTLMNAMEN1 | |
| SCHEMBL18540941 | 0.72 | HPGD (0.49) | ALDH1A1MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809583-B2 | Oxazolidine-based compound and selective androgen receptor agonist comprising same | DONG-A ST CO., LTD. (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | DONG-A ST CO., LTD. (KR) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050955-A1 | OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME | AR, SHBG, MUSK | ALDH1A1 1632/4885AR 1/4885MAPT 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.